Spots Global Cancer Trial Database for A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Official Title: An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
Study ID: NCT03316794
Conditions
Interventions
Study Description
Brief Summary: This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005. This study consists of 2 parts: Part A (dose regimen finding) followed by Part B (dose expansion).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago /ID# 169231, Chicago, Illinois, United States
Washington University School /ID# 169177, Saint Louis, Missouri, United States
Memorial Sloan Kettering /ID# 201016, New York, New York, United States
Gabrail Cancer Center Research /ID# 168756, Canton, Ohio, United States
Oklahoma University /ID# 200937, Oklahoma City, Oklahoma, United States
Tennessee Oncology-Sarah Cannon Research Institute /ID# 169233, Nashville, Tennessee, United States
Baylor University /ID# 169860, Houston, Texas, United States
MD Anderson Cancer Center /ID# 169232, Houston, Texas, United States
Contact Details
Name: AbbVie Inc.
Affiliation: AbbVie
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
